A Retrospective Cohort Study on Predictors for Rehospitalizations With Recurrence of Atrial Fibrillation Post-Catheter Ablation for Atrial Fibrillation

Farhan A. Shah, Nathan Mahler, Sean M. Winkle, Priscilla Fujikawa, Brandon Nader, Juan Rodriguez

1. Internal Medicine, LewisGale Medical Center, Salem, USA  
2. Internal Medicine, Edward Via College of Osteopathic Medicine, Blacksburg, USA  
3. Cardiology, LewisGale Medical Center, Salem, USA

Corresponding author: Brandon Nader, banader@vt.edu

Abstract

Atrial fibrillation (AF) is the most common cardiac arrhythmia and is increasing in prevalence due to an aging population. Although medications for rhythm and rate control remain the first-line treatment options for many patients, difficulties in include arrhythmia relapse and drug side effects. Catheter ablation or radiofrequency is an alternative treatment modality that can isolate where ectopic arrhythmic sites originate. Several previous studies have examined post-ablation complications and hospitalization rates for arrhythmia recurrence. However, many of these studies used patient data from before 2015. We examined the following data using recent records: pre-procedural patient characteristics, rates of post-procedural hospitalizations with documented recurrence of AF, and patient risk factors associated with these recurrences.

Categories: Cardiology, Internal Medicine  
Keywords: atrial fibrillation, catheter ablation, rehospitalization, cardiac arrhythmia, cardiac electrophysiology

Introduction

Radiofrequency catheter ablation is a commonly used method for the treatment of tachyarrhythmias. Atrial fibrillation (AF) is the most common arrhythmia and has an increasing prevalence with our aging population [1]. While the use of medications for rhythm and rate control remains the first-line treatment for many patients, difficulties including rhythm relapse and drug side effects complicate their use. Radiofrequency is used to isolate the pulmonary vein, where most ectopic arrhythmic sites originate [2]. Post-procedural complications include hemorrhage, hematomas, pulmonary vein stenosis, recurrence of atrial fibrillation, cardiac tamponade, and hospitalization after ablation [3,4]. Various studies have looked at post-ablation complications and hospitalization rates for arrhythmia recurrence [5-7]. Many of these studies were conducted or used patient data from before 2015. Improvements in ablation techniques, and in our understanding of the mechanisms of AF, have led to improved patient outcomes. An important aspect of reducing the incidence of post-procedural complications is having current data regarding underlying patient factors that influence these complications [1]. In an effort to provide contemporary data regarding this patient population, we examined pre-procedural patient characteristics, rates of post-procedural hospitalizations with documented recurrence of AF, and patient risk factors associated with these recurrences.

Materials And Methods

The patient population studied ranged from age 40-85 years old, and was pooled from Hospital Corporation of America (HCA) facilities throughout the United States using HCA’s central database. Existing data from this source is de-identified and contains inpatient admission files including all diagnoses, procedures, and pharmacological data. We first identified all patients who underwent radioablation for atrial fibrillation in the year 2018 by using the Current Procedural Terminology (CPT) code of 93656. Data on age and gender were acquired. Patients were identified as specifically having a diagnosis of paroxysmal AF or persistent AF at the time of ablation based on having documented International Classification of Disease tenth edition (ICD-10) codes of 148.0 or 148.1, respectively. Pre-procedural patient medical histories, including cardiovascular medications, were obtained at the time of ablation using ICD-10 codes, family history queries, and home medication list queries.

Medical histories were reviewed with particular emphasis on risk factors including cardiovascular risk factors (diabetes type 1 or type 2, hypertension, hyperlipidemia, and family history of heart disease), documented cardiovascular disease (heart failure with preserved or reduced ejection fraction, history of heart disease, and history of vascular disease), and other select pathologies (including chronic kidney disease, history of pulmonary embolism, or stroke). Prescribed cardiovascular medications that were being taken at the time of...
Ablation were documented, as based on medication verifications performed by staff before the procedures. Medication groups included HMG CoA reductase inhibitors (HMGCRs), angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), vasodilators (including nitrates and hydralazine), beta-blockers, calcium channel blockers, thiazide diuretics, non-thiazide diuretics (including potassium-sparing and loop diuretics), platelet aggregation inhibitors, direct factor Xa inhibitors, and cyclooxygenase inhibitors (including non-steroidal inflammatory drugs and aspirin).

We then identified all patients who were hospitalized within 90 days and 365 days following their procedure who had documented recurrence of atrial fibrillation during that hospitalization based on the ICD-10 codes previously mentioned. These re-admitted patients were further analyzed based on their pre-procedural medical history, family history, and medications to determine possible associations between these characteristics and incidents of hospitalization with AF recurrence. Odds ratios were calculated with corresponding P values (significance cutoff of p < 0.05) and confidence intervals.

Results

As seen in Table 1, we identified 9,189 patients who underwent radioablation for atrial fibrillation in 2018. The mean age was 66 years old and 63% of the patients were male. 50% of the patients had paroxysmal atrial fibrillation, 37% had persistent atrial fibrillation. Hypertension was a common co-morbidity, recorded in 47% of patients and 35% were being treated with an ACEI or an ARB, while 48% were on a beta-blocker. Approximately 25% had a history of heart failure and diabetes. 73% of the patients were on anticoagulation and 24% were on a platelet aggregation inhibitor. 40% were on an HMG CoA reductase inhibitor.
Baseline characteristics of the patients (n = 9189)

| Characteristics                                      | No. (%)     |
|------------------------------------------------------|-------------|
| Age (years) – min-max (mean)                         | 40-85 (66)  |
| Male sex - no. (%)                                   | 5785 (63)   |
| Female sex - no. (%)                                 | 3404 (37)   |
| Paroxysmal atrial fibrillation - no. (%)             | 4571 (50)   |
| Persistent atrial fibrillation - no. (%)             | 3366 (37)   |
| Cardiovascular risk factors - no. (%)                |             |
| Hypertension                                         | 4343 (47)   |
| Diabetes                                             | 2105 (23)   |
| Hyperlipidemia                                       | 3398 (37)   |
| Family history of heart disease                      | 839 (9)     |
| Chronic kidney disease                               | 901 (9)     |
| Cardiovascular disease - no. (%)                     |             |
| Heart failure                                        | 2192 (24)   |
| History of heart disease                             | 330 (4)     |
| History of vascular disease                          | 135 (1)     |
| History of pulmonary embolism and stroke             | 257 (3)     |
| Home medications - no./total no. (%)                 |             |
| HMG CoA reductase inhibitors                         | 3653 (40)   |
| ACEI                                                 | 1760 (19)   |
| ARBs                                                 | 1496 (16)   |
| Coronary vasodilators                                | 318 (3)     |
| Antihypertensives, vasodilators                      | 532 (8)     |
| Beta-blockers                                        | 4405 (48)   |
| Calcium channel blockers                             | 2228 (24)   |
| Thiazide diuretics, aoe inhibitor-thiazide or thiazide-like diuretic | 757 (8)     |
| Potassium sparing diuretics, combinations            | 57 (1)      |
| Platelet aggregation inhibitors                      | 2162 (24)   |
| Direct factor Xa inhibitors                          | 6713 (73)   |
| NSAIDs, cyclooxygenase Inhibitors                    | 1117 (12)   |

**TABLE 1: Baseline characteristics of the patients including patient demographics, comorbidities, and home medications shown as percentage.**

HMG: hydroxymethylglutaryl; ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin receptor blockers; NSAIDs: nonsteroidal anti-inflammatory drugs.

Table 2 illustrates the following:

90-day readmission for atrial fibrillation

In the 90 days following catheter ablation for atrial fibrillation, patients who were readmitted were more likely to be female (95% CI 1.037-1.376, p-value: 0.014), have heart failure (95% CI 1.25-1.789, p-value <
0.05), chronic kidney disease (95% CI 1.028-1.605, p-value: 0.027), be on HMG CoA reductase inhibitors (95% CI 1.069-1.499, p-value: 0.005), and on coronary vasodilators (95% CI 1.001-1.914, p-value: 0.049). On the other hand, those who were readmitted were less likely to be on an ARB (95% CI 0.659-0.986, p-value: 0.036).

365-day readmission for atrial fibrillation

Similarly to the 90-day readmission results, our 365-day analysis revealed that patients who were readmitted were more likely to have heart failure (95% CI 1.169-1.595, p-value < 0.05), HMG CoA reductase inhibitors (95% CI 1.049-1.364, p-value: 0.008), female gender (95% CI 1.088-1.388, p-value: 0.001), chronic kidney disease (95% CI 1.043-1.537, p-value: 0.017), ARBs (95% CI 0.699-0.986, p-value: 0.034). In addition, they were also more likely to be on platelet aggregation inhibitors (95% CI 1.067-1.407, p-value: 0.004) and have diabetes (95% CI 1.009-1.332, p-value: 0.037). At one year, patients readmitted had lower incidences of ARB treatment (95% CI 0.699-0.986, p-value: 0.034).
TABLE 2: 90- and 365-day readmission for atrial fibrillation according to comorbidities and home medications.

| Comorbidity                                      | 90 days Odds Ratio | p-value | 95% CI       | 365 days Odds Ratio | p-value | 95% CI       |
|-------------------------------------------------|--------------------|---------|--------------|---------------------|---------|--------------|
| Heart failure                                   | 1.495              | <0.05   | 1.25-1.789   | 1.365               | <0.05   | 1.169-1.595  |
| HMG CoA reductase inhibitors                    | 1.244              | 0.005   | 1.069-1.449  | 1.196               | 0.008   | 1.049-1.364  |
| Female                                          | 1.195              | 0.014   | 1.037-1.376  | 1.229               | 0.001   | 1.088-1.388  |
| Chronic kidney disease                          | 1.285              | 0.027   | 1.028-1.605  | 1.266               | 0.017   | 1.043-1.537  |
| ARBs                                            | 0.806              | 0.036   | 0.659-0.986  | 0.83                | 0.034   | 0.699-0.986  |
| Coronary vasodilators                           | 1.384              | 0.049   | 1.001-1.914  | 1.32                | 0.054   | 0.995-1.752  |
| Platelet aggregation inhibitors                 | 1.005              | 0.948   | 0.853-1.185  | 1.226               | 0.004   | 1.067-1.407  |
| Diabetes                                        | 1.127              | 0.146   | 0.959-1.325  | 1.159               | 0.037   | 1.009-1.332  |
| History of pulmonary embolism, stroke           | 1.349              | 0.102   | 0.942-1.933  | 1.125               | 0.488   | 0.807-1.567  |
| Hyperlipidemia                                  | 0.9                | 0.168   | 0.774-1.046  | 0.915               | 0.18    | 0.804-1.042  |
| Family history of heart disease                 | 1.167              | 0.173   | 0.934-1.458  | 1.085               | 0.418   | 0.891-1.321  |
| History of heart disease                        | 1.248              | 0.178   | 0.904-1.724  | 1.162               | 0.305   | 0.872-1.548  |
| ACEI                                            | 0.899              | 0.252   | 0.748-1.079  | 0.907               | 0.226   | 0.775-1.062  |
| Hypotensives, sympatholytic                     | 0.693              | 0.282   | 0.364-1.316  | 0.851               | 0.527   | 0.516-1.404  |
| NSAIDs                                          | 1.102              | 0.347   | 0.9-1.351    | 1.1                 | 0.288   | 0.923-1.311  |
| Vaso dilators                                   | 0.869              | 0.364   | 0.643-1.176  | 1.016               | 0.901   | 0.793-1.301  |
| Direct factor Xa inhibitors                     | 1.068              | 0.414   | 0.912-1.249  | 1.048               | 0.494   | 0.916-1.2    |
| Beta-blockers                                   | 0.943              | 0.424   | 0.617-1.089  | 0.977               | 0.715   | 0.683-1.106  |
| Thiazide Diuretics                              | 1.08               | 0.546   | 0.841-1.388  | 0.959               | 0.714   | 0.769-1.198  |
| Hypertension                                    | 1.041              | 0.636   | 0.882-1.227  | 1.011               | 0.874   | 0.878-1.165  |
| Calcium Channel Blockers                        | 1.034              | 0.667   | 0.86-1.213   | 1.007               | 0.919   | 0.877-1.157  |
| Adrenergic inhibitors                           | 0.967              | 0.766   | 0.778-1.203  | 1.162               | 0.108   | 0.967-1.395  |
| History of vascular disease                     | 1.036              | 0.896   | 0.607-1.768  | 0.971               | 0.903   | 0.608-1.552  |

Discussion

The use of catheter ablation for treatment of atrial fibrillation is a common and effective procedure that provides rhythm control where medication use has proved to be ineffective [8]. Medication failure has been defined as failure to adequately control the heart rate, or ongoing symptoms of palpitations, dizziness, and shortness of breath [9]. Ablation is most useful in patients with paroxysmal or persistent AF, but a growing body of evidence indicates that there may be mortality benefits to early use of rhythm control [10]. As a result, more consideration is being given to using ablation as first-line treatment in asymptomatic patients for rhythm control. Recurrence rates of AF after ablations have decreased dramatically with improved ablation technique, but remains a problem [11]. In this retrospective cohort study, we evaluated a total of 9189 patients who had a catheter ablation procedure for AF in 2018 at multiple institutions throughout the United States. We then identified patients who were re-hospitalized in the subsequent year with documented recurrence of atrial fibrillation. Overall, 1,533 patients (16.68%) were readmitted within the
rehospitalizations in other populations and healthcare systems. This cohort study should prompt further examination of post-catheter ablation complications and persistent AF. Studies of post-ablation outcomes are extremely varied in their selection of patient age, patients with persistent AF, which would require a further sub-analysis of patients with paroxysmal versus reporting of duration prior to procedures. There may be some risk factors that are only of significance in other heart failure populations that are at greatest risk for recurrence. Specific data regarding diabetes, which heart failure type may assist with defining prevention of recurrence.

Conclusions

Some variables that were statistically significant risk factors for AF recurrence in previous studies did not show significance in our study, including hypertension. This may be due to the lack of an outpatient data contribution or the duration of our study. Notably, other studies have only found hypertension to be significant in a two-year follow-up period. Diabetes was a significant factor in the 365-day recurrence group but not in the 90-day readmission group. Metabolic syndrome has been found to have a similar pattern in other studies. Hyperlipidemia was not a significant risk factor for recurrence in our study. Interestingly, the use of HMGRs was significantly associated with increased recurrence rates, in our study. Hyperlipidemia was possibly underreported in our patient group, as it is noted that 45.25% of patients in the 90-day readmission group were taking HMGRs while only 37.74% had documented hyperlipidemia. A similar discrepancy was seen in the 365-day readmission group. We conclude that hyperlipidemia is likely a significant risk factor for recurrence in this study, as the accurate number of patients with hyperlipidemia is likely reflected by the number of patients who were on statin therapy. Statin therapy may not reduce the impact of hyperlipidemia. Prior studies have found elevated low-density lipoprotein cholesterol to be a significant risk for AF recurrence, but saw no association of statin therapy and improved recurrence rates. Further data is needed, including trended cholesterol levels, length of statin use, and potency of the statin used. Other medications of significance included coronary vasodilators and ARBs. Vasodilators (including nitroglycerine) were associated with increased AF recurrence risk, which may reflect that this population was more likely to have coronary artery disease. Lastly, we note that ARBs were associated with a decreased risk of AF, but ACEIs were not. More data is needed regarding dosing and compliance of these medications before a substantial conclusion could be drawn regarding a protective role of ARBs in the prevention of recurrence.

Some limitations to the study centered around difficulty with defining specific parameters for risk factors when using a large patient database. Specific data reflecting heart failure type may assist with defining which heart failure populations that are at greatest risk for recurrence. Specific data regarding diabetes, including A1cs and diabetic type may show impact of treatment on that patient group.

Conclusions

Other studies have shown an important relationship between duration of AF prior to ablation and recurrence rates. Confidently attributing recurrence to AF duration is difficult given high variation in reporting of duration prior to procedures. There may be some risk factors that are only of significance in patients with persistent AF, which would require a further sub-analysis of patients with paroxysmal versus persistent AF. Studies of post-ablation outcomes are extremely varied in their selection of patient age, comorbidities, procedure type, which is an added challenge when comparing findings of other institutions. This cohort study should prompt further examination of post-catheter ablation complications and rehospitalizations in other populations and healthcare systems.
Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

This research was supported (in whole or in part) by HCA and/or an HCA-affiliated entity. The views expressed in this publication represent those of the author(s) and do not necessarily represent the official views of HCA or any of its affiliated entities.

References

1. Hong KL, Borges J, Glover B: Catheter ablation for the management of atrial fibrillation: current technical perspectives. Open Heart. 2020, 7:10.1136/openhrt-2019-001207
2. Parameswaran R, Al-Kaisey AM, Kelman JM: Catheter ablation for atrial fibrillation: current indications and evolving technologies. Nat Rev Cardiol. 2021, 18:210-25. 10.1038/s41573-020-00451-x
3. Vanissen C, Velthuis BK, Hassanik RI, et al.: Incidence of pulmonary vein stenosis after radiofrequency catheter ablation of atrial fibrillation. JACC Clin Electrophysiol. 2017, 5:589-98. 10.1016/j.jacep.2017.02.003
4. Samuel M, Almohammadi M, Tsadok MA, et al.: Population-based evaluation of major adverse events after catheter ablation for atrial fibrillation. JACC Clin Electrophysiol. 2017, 3:1425-33. 10.1016/j.jacep.2017.04.010
5. Hinckens G: The Multicentre European Radiofrequency Survey (MERFS): complications of radiofrequency catheter ablation of arrhythmias. The Multicentre European Radiofrequency Survey (MERFS) investigators of the Working Group on Arrhythmias of the European Society of Cardiology. Eur J Heart J. 1993, 14:1644-53. 10.1093/eurheartj/14.12.1644
6. Calkins H, Yong P, Miller JM, et al.: Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction: final results of a prospective, multicenter clinical trial. The Atakr Multicenter Investigators Group. Circulation. 1999, 99:262-70. 10.1161/01.cir.99.2.262
7. Capato R, Calkins H, Chen SA, et al.: Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for atrial fibrillation. Curr Heart Rhythm. 2010, 3:52-8. 10.1016/CIRCEP.109.859116
8. Mujović N, Mariniković M, Lenarczyk R, Tiltz R, Potpara TS: Catheter ablation of atrial fibrillation: an overview for clinicians. Adv Ther. 2017, 34:897-917. 10.1007/s12325-017-0590-z
9. Medical Advisory Secretariat: Ablation for atrial fibrillation: an evidence-based analysis. Ont Health Technol Assess Ser. 2006, 6:1-63.
10. Kirchhof P, Camm AJ, Goette A, et al.: Early rhythm-control therapy in patients with atrial fibrillation . N Engl J Med. 2020, 383:1305-16. 10.1056/NEJMoa190422
11. Pallisgaard JL, Gislason GH, Hansen J, Johannessen A, Torp-Pedersen C, Rasmussen PV, Hansen ML: Temporal trends in atrial fibrillation recurrence rates after ablation between 2005 and 2014: a nationwide Danish cohort study. Eur Heart J. 2018, 39:442-9. 10.1093/europheart/eby466
12. Garvanski I, Simova I, Angelkov L, Matveev M: Predictors of recurrence of AF in patients after radiofrequency ablation. Eur Cardiol. 2019, 14:165-8. 10.15420/ecr.2019.30.2
13. Themistoclakis S, Schwikerdt RA, Sallab WI, et al.: Clinical predictors and relationship between early and late atrial tachyarrhythmias after pulmonary vein antrum isolation. Heart Rhythm. 2008, 5:679-85. 10.1016/j.hrthm.2008.01.051
14. Zink MD, Chua W, Zeemering S, et al.: Predictors of recurrence of atrial fibrillation within the first 3 months after ablation. Europace. 2020, 22:1337-44. 10.1093/europace/euaa152
15. Freeman IV, Tabada GH, Reynolds K, Sung SH, Liu Y, Gupta N, Go AS: Contemporary procedural complications, hospitalizations, and emergency visits after catheter ablation for atrial fibrillation. Am J Cardiol. 2018, 121:602-8. 10.1016/j.amjcard.2017.11.054
16. Pappone C, Oroto G, Rosanio S, et al.: Atrial electroanatomic remodeling after circumferential radiofrequency pulmonary vein ablation: efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation. Circulation. 2001, 104:2539-44. 10.1161/hc4601.098517
17. Berraucio A, Tamborero D, Mont L, et al.: Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. Eur Heart J. 2007, 28:836-41. 10.1093/eurheartj/ehm027
18. Santangeli P, Di Blasi L, Basile E, Al-Ahmad A, Natale A: Outcomes in women undergoing electrophysiological procedures. Arrhythm Cardiol Physiol Rev. 2015, 2:41-4. 10.15420/acr.2015.2.1.41
19. Li A, Chen Y, Wang W, Su L, Ling Z: Association of clinical predictors with recurrence of atrial fibrillation after catheter ablation. Ann Non invasive Electrocadiol. 2020, 25:e12787. 10.1111/anec.12787